Poliomyelitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Poliomyelitis – Drugs In Development, 2024 report and make more profitable business decisions.
Polio is a highly infectious disease caused by a virus. It invades the nervous system and can cause total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck, and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.
The Poliomyelitis drugs in development market research report provide comprehensive information on the therapeutics under development for Poliomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Poliomyelitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 38 molecules, with 26 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Poliomyelitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Poliomyelitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Poliomyelitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Beijing Health Guard Biotechnology IncBeijing Institute of Biological Products
Beijing Minhai Biotechnology Co Ltd
Beijing Tiantan Biological Products Co Ltd
Bharat Biotech Ltd
Biological E Ltd
Biological Mimetics Inc
Boryung Pharmaceutical Co Ltd
Butantan Institute
CanSino Biologics Inc
Fighting Infectious Diseases in Emerging Countries
Helix Biogen Institute
Indian Immunologicals Ltd
International Vaccine Institute
Intravacc BV
Johnson & Johnson
KM Biologics Co Ltd
LG Chem Ltd
Massachusetts Institute of Technology
Micron Biomedical Inc
Nanolek
National Institute of Hygiene and Epidemiology
Panacea Biotec Ltd
PATH
Sanofi
Serum Institute of India Pvt Ltd
Sinopharm Zhongsheng Biotechnology Research Institute Co Ltd
Statens Serum Institut
Statera Biopharma Inc
University of Antwerp
University of Leeds
Wuhan Institute of Biological Products Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Poliomyelitis reports